Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer

BJU International

Volumn 98, Issue 5, 2006, Pages 989-995

  Muir, Gordon ^a   Rajbabu, Krishnamoorthy ^a   Callen, Charles ^a   Fabre, John W ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic response; Genetic instability; Prostate cancer; Skin allografts; Tumour immunotherapy; Tumour neo antigen

Indexed keywords

BICALUTAMIDE; DIETHYLSTILBESTROL; ERYTHROCYTE ANTIBODY; ESTRADIOL; GENOMIC DNA; GONADORELIN AGONIST; GOSERELIN; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; LEUPRORELIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; FULL THICKNESS SKIN GRAFT; GENETIC STABILITY; HLA TYPING; HUMAN; HUMAN TISSUE; MALE; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SKIN ALLOGRAFT; T LYMPHOCYTE; TUMOR IMMUNITY; URETER STENT; URINARY TRACT OBSTRUCTION; URINE RETENTION;

AGED; AGED, 80 AND OVER; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33749580995     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06421.x     Document Type: Article

References (30)

1. Melief CJ. Cancer immunology: cat and mouse games. Nature 2005; 437: 41-2
2. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13
3. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-66
4. Saeterdal I, Bjorheim J, Lislerud K et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 2001; 98: 13255-60
5. Marx J. Debate surges over the origins of genomic defects in cancer. Science 2002; 297: 544-6
6. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11
7. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437: 141-6
8. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8
9. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4
10. Fabre JW. The allogeneic response and tumor immunity. Nat Med 2001; 7: 649-52
11. Bach FH, Voynow NK. One-way stimulation in mixed leukocyte cultures. Science 1966; 153: 545-7
12. Nisbet NW, Simonsen M, Zaleski M. The frequency of antigen-sensitive cells in tissue transplantation. A commentary on clonal selection. J Exp Med 1969; 129: 459-67
13. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973-81
14. Bevan MJ. High determinant density may explain the phenomenon of alloreactivity. Immunol Today 1984; 5: 128-30
15. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990; 11: 83-8
16. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994; 179: 1155-61
17. Gjertsen HA, Lundin KE, Hansen T, Thorsby E. T cells specific for viral antigens presented by HLA-Dw4 recognize DR13 on allogeneic cells: a possible mechanism for induction of rejection. Transplant Proc 1993; 25: 70-1
18. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12: 1868-75
19. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-82
20. Doggrell SA. Which drug combination for hormone-refractory prostate cancer? Expert Opin Pharmacother 2005; 6: 667-70
21. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992; 4: 661-71
22. Wolfram RM, Budinsky AC, Brodowicz T et al. Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer 2000; 88: 239-44
23. Perez VL, Henault L, Lichtman AH. Endothelial antigen presentation: stimulation of previously activated but not naive TCR-transgenic mouse T cells. Cell Immunol 1998; 189: 31-40
24. Leach FS. Microsatellite instability and prostate cancer: clinical and pathological implications. Curr Opin Urol 2002; 12: 407-11
25. Old LJ, Boyse EA. Immunology of experimental tumors. Annu Rev Med 1964; 15: 167-86
26. Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11: 4469-78
27. Fabre JW. The role of polymorphic donor peptides in allograft recognition and rejection. Immunol Rev 1996; 154: 21-43
28. Newton DA, Romano C, Gattoni-Celli S. Semiallogeneic cell hybrids as therapeutic vaccines for cancer. J Immunother 2000; 23: 246-54
29. Eapen M, Rubinstein P, Zhang MJ et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006; 24: 145-51
30. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3